Results 41 to 50 of about 63,510 (311)
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Summary: Antigen presentation to T cells in major histocompatibility complex class II (MHC class II) requires the conversion of early endo/phagosomes into lysosomes by a process called maturation.
Maksim V. Baranov +12 more
doaj +1 more source
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Autophagy Proteins in Phagocyte Endocytosis and Exocytosis
Autophagy was initially described as a catabolic pathway that recycles nutrients of cytoplasmic constituents after lysosomal degradation during starvation.
Christian Münz
doaj +1 more source
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Abstract Background A methodology to assess the immune microenvironment (IME) of non‐small cell lung cancer (NSCLC) has not been established, and the prognostic impact of IME factors is not yet clear. Aims This study aimed to assess the IME factors and evaluate their prognostic values. Methods and Results We assessed CD8+ tumor‐infiltrating lymphocyte (
Yukihiro Terada +16 more
wiley +1 more source
The cluster of differentiation 1 (CD1) molecule differs from major histocompatibility complex class I and II because it presents glycolipid/lipid antigens. Moreover, the CD1-restricted T cells that recognize these self and foreign antigens participate in
Seohyun Kim, Sumin Cho, Ji Hyung Kim
doaj +1 more source
Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members.
Hong Zhou +13 more
doaj +1 more source
Mutations and selection in the generation of class II histocompatibility antigen polymorphism. [PDF]
A comparison of seven human DR and DC class II histocompatibility antigen beta-chain amino acid sequences indicates that the allelic variation is of comparable magnitude within the DR and DC beta-chain genes. Silent and replacement nucleotide substitutions in six DR and DC beta-chain sequences, as well as in seven murine class II sequences (three I-A ...
K, Gustafsson +8 more
openaire +2 more sources
Development of human monoclonal antibodies against TARM1 by yeast display
Human monoclonal antibodies against TARM1 are generated by yeast display‐guided selection. These antibodies bind to soluble and cell‐surface forms of TARM1. Also, these antibodies exhibit agonistic activity in the NFAT‐GFP reporter assay, indicating that TARM1 signaling can be functionally modulated by antibodies and suggesting TARM1 as a potential ...
Rikio Yabe +5 more
wiley +1 more source

